SecBot SecBot

CMMB

Chemomab Therapeutics Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001534248 Biotech & Drug Discovery
$1.62 +0.09 (+5.88%)
Nov 16 4:00 PM ET · prev $1.53
Market cap
$11.3M
Nano cap
Median target
$5.00
+209% · range $5.00–5.00
Next earnings
Nov 18
in 1 day · EPS est. $0.00
1 year
−37.7%
from $2.60 · Nov 17
30 days
+38.5%
from $1.17
52-week range
$1.00–2.83
−43% from high · low Oct 26
Avg volume 20D
63.5K
Oct 30 spike 224.5K
Short interest
5.1K
≈0.1% of shares · −63.0%
Days to cover
1.0
at average volume
Insider net
+$13.7K
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 1 bearish · 0 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 9/9 ·Next Earnings date, Nov 18, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $20.2K at an average $2.07. 1 insider sold $6.5K. Price is 22% below their cost.

  • InstitutionsMIXED

    Q3 2026: 0 added (0 new), 2 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.010 → $0.000 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −63.0% to 5.1K shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendRANGE

    1% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BNP PARIBAS FINANCIAL MARKETSTRIM3,300$3.9K
MORGAN STANLEYTRIM1,600$1.9K
CITADEL ADVISORS LLCADD95,311$154.4K
RHUMBLINE ADVISERSADD30,529$49.5K
UBS Group AGNEAR_EXIT8$13.00
RHUMBLINE ADVISERSADD17,856$29.5K
JANE STREET GROUP, LLCTRIM15,598$25.7K
BNP PARIBAS FINANCIAL MARKETSADD8,125$13.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +209%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Aug 27, 2025Oppenheimer
MAINTAIN
MAINTAINOutperform
May 16, 2025Oppenheimer
MAINTAIN
MAINTAINOutperform
Feb 20, 2025Maxim Group
MAINTAIN
MAINTAINBuy
Nov 15, 2024Oppenheimer
REITERATE
REITERATEOutperform
May 13, 2024Maxim Group
INITIATE
INITIATEBuy
May 6, 2024Oppenheimer
UPGRADE
UPGRADEOutperform

Insider ledger

Form 4
$20.2K
bought · 1 insider
$6.5K
sold · 1 insider
−21.6%
vs their $2.07 cost
DateInsiderTypeValue
Aug 28, 2026
Cohen Neil Harris
Director
Aug 28, 2026
SELL$2.8K
Aug 27, 2026
Cohen Neil Harris
Director
Aug 27, 2026
SELL$3.7K
May 29, 2026
Mor George Adi
Chief Executive Officer
May 29, 2026
BUY$10.0K
May 29, 2026
Mor George Adi
Chief Executive Officer
May 29, 2026
OTHER31,712 sh
May 29, 2026
Mor George Adi
Chief Executive Officer
May 29, 2026
BUY$10.2K
May 29, 2026
Mor George Adi
Chief Executive Officer
May 29, 2026
OTHER18,750 sh
Mar 16, 2026
Cohen Neil Harris
Director
Mar 16, 2026
AWARD5,172 sh
Mar 16, 2025
Cohen Neil Harris
Director
Mar 16, 2025
AWARD3,821 sh

Earnings setup

Estimates
Nov 18
reports in 1 day
$0.00
EPS estimate, this quarter
+100%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.00$0.00–$0.00No data$0.00
Next Q$0.00$0.00–$0.00No data$0.00
Current FY-$0.02-$0.02–-$0.02+0.0%$0.00
Next FY-$0.03-$0.03–-$0.03+0.0%$0.00

Short side

FINRA· Oct 30, 2026
5,139
shares short
-63.0%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
Scipher Medicine Corporation filed a Schedule 13D disclosing beneficial ownership of 74,576,240 ordinary shares of…
SC 13D · Impact 5/10
Nov 10, 2026 SEC
Chemomab Therapeutics filed a DEFA14A supplement to its proxy statement/prospectus for the December 4, 2026 special…
DEFA14A · Impact 5/10
Nov 3, 2026 SEC
Chemomab Therapeutics filed a Form 6-K to incorporate by reference into its registration statements the S-4…
6-K · Impact 4/10
Nov 2, 2026 Press
Chemomab Therapeutics announced that the SEC declared effective the S-4 registration statement for its proposed merger…
Impact 5/10
Nov 2, 2026 M&A
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
The SEC has declared effective the Form S-4 Registration Statement and definitive proxy for the prop
Sep 30, 2026 Inst.
BNP PARIBAS FINANCIAL MARKETS · TRIM
3,300 shares ($3.9K)
Sep 30, 2026 Inst.
MORGAN STANLEY · TRIM
1,600 shares ($1.9K)
Aug 28, 2026 Insider
Cohen Neil Harris sold 1,000 shares
Director @ $2.80 ($2.8K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

13 filings · 2 press releases · 1 bullish · 1 bearish · 11 neutral
All CMMB filing & press-release reports (15)